Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186502 | 0.82 | ALDH1A1 (0.59) | ALDH1A1NQO2TAAR1FFAR4CYP1A1 | |
| SCHEMBL168353 | 0.82 | ALDH1A1 (0.69) | ALDH1A1NQO2TAAR1CYP1A1CYP1B1 | |
| SCHEMBL233828 | 0.82 | ALDH1A1 (0.69) | ALDH1A1NQO2CYP1A1CYP1B1CYP3A4 | |
| Methane SCHEMBL28126699 | 0.79 | ALDH1A1 (0.56) | ALDH1A1NQO2TAAR1FFAR4CYP1A1 | |
| SCHEMBL17204036 | 0.76 | KAT6A (0.38) | ALDH1A1FFAR4MAOA | |
| SCHEMBL11885 | 0.73 | ALDH1A1 (0.48) | ALDH1A1NQO2TAAR1FFAR4CYP1A1 | |
| SCHEMBL1805052 | 0.73 | ALDH1A1 (0.48) | ALDH1A1FFAR4CYP1A1CYP1B1CYP3A4 | |
| SCHEMBL7234709 | 0.73 | ALDH1A1 (0.55) | ALDH1A1NQO2TAAR1CYP1A1CYP1B1 | |
| SCHEMBL17203920 | 0.73 | APP (0.34) | ALDH1A1 | |
| SCHEMBL330569 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292494-A | Isoquinoline carboxylic acid compound and preparation method and application thereof | 江苏苏中药业集团股份有限公司 | 2021-08-24 | — | — | CN | claimed |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | claimed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | claimed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-10029992-B2 | Diaminotriazine compounds and their use as herbicides | BASF SE (DE) | 2018-07-24 | — | — | US | claimed |
| EP-3134391-A1 | DIAMINOTRIAZINE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2017-03-01 | — | — | EP | claimed |
| US-20170044114-A1 | Diaminotriazine compounds and their use as herbicides | BASF SE (DE) | 2017-02-16 | — | — | US | claimed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | claimed |
| US-20160317523-A1 | Treatment of Retinopathy of Prematurity (ROP) | THE CLEVELAND CLINIC FOUNDATION | 2016-11-03 | — | — | US | claimed |
| WO-2015162166-A1 | DIAMINOTRIAZINE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2015-10-29 | — | — | WO | claimed |
| US-7863292-B2 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. (US) | 2011-01-04 | — | — | US | claimed |
| US-7629357-B2 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. (US) | 2009-12-08 | — | — | US | claimed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | claimed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | claimed |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. | 2007-07-05 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | ALDH1A1 1908/4885NQO2 323/4885TAAR1 3419/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | ALDH1A1 1908/4885NQO2 323/4885TAAR1 3419/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | ALDH1A1 1476/4885NQO2 218/4885TAAR1 3220/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | ALDH1A1 1908/4885NQO2 323/4885TAAR1 3419/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | ALDH1A1 1476/4885NQO2 218/4885TAAR1 3220/4885 |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, EGLN3, EGLN2 | ALDH1A1 1908/4885NQO2 323/4885TAAR1 3419/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | ALDH1A1 1829/4885NQO2 1564/4885TAAR1 3944/4885 |
| US-10029992-B2 | Diaminotriazine compounds and their use as herbicides | NR4A3, CBR3, RCOR3 | ALDH1A1 941/4885NQO2 92/4885TAAR1 951/4885 |
| US-20160317523-A1 | Treatment of Retinopathy of Prematurity (ROP) | VEGFA, ALDH1A2, PGF | ALDH1A1 149/4885NQO2 1251/4885TAAR1 2385/4885 |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | ALDH1A1 389/4885NQO2 926/4885TAAR1 3146/4885 |
| US-20170044114-A1 | Diaminotriazine compounds and their use as herbicides | NR4A3, CBR3, RCOR3 | ALDH1A1 935/4885NQO2 94/4885TAAR1 947/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | ALDH1A1 946/4885NQO2 774/4885TAAR1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.